Advanced pancreatic cancer
Conditions
Interventions
Experimental group:PD-1 inhibitor combined with chemotherapy
Sponsors
Chizhou people's Hospital, Anhui Province
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Patients with unresectable, recurrent and / or metastatic pancreatic cancer confirmed by cytology or histology; 3. Have at least one evaluable lesion judged according to rrecist version 1.1 (spiral CT scan length of measurable lesion >=10mm or short diameter of enlarged lymph node >=15mm according to RECIST version 1.1); 4. ECoG PS The following criteria should be met: (1) HB >=80 g/L; ANC >=1.5 x 10^9/L; PLT >=80 x 10^9/L; (2) biochemical examination should meet the following criteria: TBIL 45 ml / min (Cockcroft Gault formula); 7. ECG is basically normal; 8. Patients have good compliance, can understand the situation of this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have received local treatment for target lesions (including local radiotherapy, interventional therapy, ultrasonic scalpel, etc.); 2. Pregnant and lactating women, or women with fertility but without contraceptive measures; 3. Severe acute infection that has not been controlled; or purulent and chronic infection, delayed wound healing; 4. Organ transplantation due to autoimmune system; 5. Patients with mental illness and AIDS; 6. Severe autoimmune diseases; 7. Those who have participated in the clinical trials of other drugs in the past 3 months; 8. The researchers think that they are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurable tumor focus;PFS, OS; | — |
Countries
China
Contacts
Public ContactXu Jinfa
Department of oncology, Chizhou people's Hospital
Outcome results
None listed